Oruka Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $105.4 million for 2025, while advancing its lead programs ORKA-001 and ORKA-002 in psoriasis and other inflammatory indications.
NASDAQ
Oruka Therapeutics' 2024 10-K filing outlines its focus on developing innovative monoclonal antibody therapies for psoriasis and other inflammatory and immunology conditions, with key programs ORKA-001 and ORKA-002 progressing towards clinical trials.
NASDAQ
ARCA Biopharma's 10-K filing details its strategic review process, Gencaro's development for atrial fibrillation, and financial position through mid-2025.